Glioblastoma Multiforme Treatment (GBM)

World Market Report

MCP16434

EXECUTIVE ENGAGEMENTS

POOL

2542
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

457
Interactions with Platform & by Email

PARTICIPANTS

76
Unique # Participated

VALIDATIONS

22
Responses Validated*

COMPANIES

33
Responses Validated*
* Login for a full stack data experience

DATE

OCT 2022

TABLES

123

PAGES

192

EDITION

8

PRICE

USD 4950

CODE

MCP16434


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

RANK

(S/A/N/T)

%

VALIDATED RESEARCH *

* S = Strong; A = Active; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
RESEARCH MODULES EXECUTIVES
  

HIGHLIGHTS & REPORT INDEX

What`s New for 2023?

» Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Glioblastoma Multiforme Treatment (GBM) Market to Reach $3.4 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Glioblastoma Multiforme Treatment (GBM) estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$3.4 Billion by 2027, growing at a CAGR of 7.5% over the analysis period 2020-2027. Radiation Therapy, one of the segments analyzed in the report, is projected to record a 7.1% CAGR and reach US$1.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Surgery segment is readjusted to a revised 8.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $590.7 Million, While China is Forecast to Grow at 6.9% CAGR
The Glioblastoma Multiforme Treatment (GBM) market in the U.S. is estimated at US$590.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$591.7 Million by the year 2027 trailing a CAGR of 6.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.5% and 6.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Chemotherapy Segment to Record 8.2% CAGR
In the global Chemotherapy segment, USA, Canada, Japan, China and Europe will drive the 8.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$310.4 Million in the year 2020 will reach a projected size of US$542.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

SELECT PLAYERS

Amneal Pharmaceuticals, Inc.; CARsgen Therapeutics; Epitopoietic Research Corporation (ERC.SA.); F. Hoffmann-La Roche AG; GBM Communications; GBM Digital Technologies; ImmunoCellular Therapeutics Ltd.; Ivy Foundation; Sapience Therapeutics; SonALAsense

SEGMENTS

» Treatment (Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy) » End-Use (Hospitals, Clinics, Ambulatory Surgery Centers)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Glioblastoma Multiforme Treatment (GBM) – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Bevacizumab (Avastin) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Bevacizumab (Avastin) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Bevacizumab (Avastin) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Temozolomide (Temodar and Temodal and Temcad) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Temozolomide (Temodar and Temodal and Temcad) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Temozolomide (Temodar and Temodal and Temcad) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Carmustine (BiCNU) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Carmustine (BiCNU) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Carmustine (BiCNU) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Glioblastoma Multiforme Treatment (GBM) Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2027
UNITED STATES
Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
USA Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2021 & 2027
CANADA
Canada Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2021 & 2027
JAPAN
Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
Japan Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2021 & 2027
CHINA
Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
China Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2021 & 2027
EUROPE
Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Europe Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2021 & 2027
FRANCE
Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
France Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2021 & 2027
GERMANY
Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
Germany Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2021 & 2027
ITALY
Italy Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2021 & 2027
UNITED KINGDOM
Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
UK Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2021 & 2027
REST OF EUROPE
Rest of Europe Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Asia-Pacific Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2021 & 2027
REST OF WORLD
Rest of World Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2021 & 2027

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com